TY - JOUR T1 - Miliary tuberculosis developing during adalimumab treatment for Behçet’s disease with uveitis JF - BMJ Case Reports JO - BMJ Case Reports DO - 10.1136/bcr-2018-226772 VL - 11 IS - 1 SP - e226772 AU - Minji Jennifer Kim AU - Nicholas Jones AU - Laura R Steeples Y1 - 2018/11/01 UR - http://casereports.bmj.com/content/11/1/e226772.abstract N2 - Tumour necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine in non-infective uveitis (NIU). Adalimumab, an anti-TNF-α monoclonal antibody, is approved for the treatment of severe NIU by the European Medicines Agency. There is a recognised risk of serious infections, including tuberculosis (TB), during anti-TNF-α therapy in systemic immune-mediated diseases. We describe miliary pulmonary TB during adalimumab therapy for severe NIU. To our knowledge, this is the first detailed report of this complication in a patient with uveitis. We present the challenges of managing vision-threatening uveitis during life-threatening infection necessitating withdrawal of adalimumab and oral immunosuppression therapy. Uveitis activity was controlled during anti-TB therapy with oral corticosteroid therapy. ER -